Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience

被引：0
|
作者：
Akira Ozawa
Nozomu Tanji
Tatsumasa Ochi
Yutaka Yanagihara
Tadahiko Kikugawa
Akiko Yamaguchi
Tetsuhiro Ikeda
Kenji Shimamoto
Katsunori Aoki
Akihiko Toshino
Masayoshi Yokoyama
机构：
[1] Ehime University Graduate School of Medicine,Department of Urology
来源：
International Journal of Clinical Oncology | 2007年 / 12卷
关键词：
Gemcitabine; Cisplatin; Metastatic urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：279 / 283
页数：4
相关论文
共 50 条
  • [21] Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma
    Yi Rang Kim
    Jae Lyun Lee
    Dalsan You
    In Gab Jeong
    Cheryn Song
    Bumsik Hong
    Jun Hyuk Hong
    Hanjong Ahn
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 141 - 153
  • [22] Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma
    Kim, Yi Rang
    Lee, Jae Lyun
    You, Dalsan
    Jeong, In Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 141 - 153
  • [23] Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen
    Takahashi, T
    Higashi, S
    Nishiyama, H
    Segawa, T
    Nakamura, E
    Kinoshita, H
    Itoh, N
    Yamamoto, S
    Kamoto, T
    Habuchi, T
    Ogawa, O
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (02) : 104 - 108
  • [24] Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Takamatsu, Dai
    Ieiri, Kosuke
    Inoue, Tomohiro
    Tsukino, Keiji
    Nakamura, Motonobu
    ONCOLOGY LETTERS, 2020, 19 (04) : 2943 - 2949
  • [25] A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin
    Lee, Eugene K.
    Jinesh, Goodwin G.
    Laing, Naomi M.
    Choi, Woonyoung
    McConkey, David J.
    Kamat, Ashish M.
    CANCER BIOLOGY & THERAPY, 2013, 14 (09) : 812 - 822
  • [26] Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function
    Carles J.
    Suárez C.
    Mesía C.
    Nogué M.
    Font A.
    Doménech M.
    Suárez M.
    Tusquets I.
    Gallén M.
    Albanell J.
    Fabregat X.
    Clinical and Translational Oncology, 2006, 8 (10) : 755 - 757
  • [27] Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: A pilot study
    Jiang, Y
    Wei, YQ
    Luo, F
    Zou, LQ
    Liu, JY
    Peng, F
    Huang, MJ
    He, QM
    CANCER INVESTIGATION, 2005, 23 (02) : 123 - 128
  • [28] Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
    Heinemann, V
    Wilke, H
    Mergenthaler, HG
    Clemens, M
    König, H
    Illiger, HJ
    Arning, M
    Schalhorn, A
    Possinger, K
    Fink, U
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1399 - 1403
  • [29] Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
    Zhang, Yuan
    Sun, Ying
    Ma, Jun
    CANCER COMMUNICATIONS, 2019, 39
  • [30] Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer
    von der Maase, H.
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S13 - S16
12345